logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2019 — NSCLC: nivolumab+ipilimumab is an effective, chemo-free alternative for first-line treatment

Another chemotherapy-sparing option for NSCLC.